Drug General Information (ID: DDIMRK4DAV)
Drug Name			Roflumilast		Drug Info		Dupilumab		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Selective Phosphodiesterase-4 Inhibitors				Interleukin Inhibitors

Mechanism of Roflumilast-Dupilumab Interaction (Severity Level: Moderate)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Roflumilast				Dupilumab
Mechanism		Immunosuppressive effects				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Roflumilast and Dupilumab

Recommended Action
Management		According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.g., in the treatment of COPD exacerbations) should be avoided if possible. Due to a lack of clinical experience, treatment with roflumilast should not be initiated, or existing treatment should be stopped, in patients receiving immunosuppressive agents and in patients with severe acute infectious diseases, cancers (except basal cell carcinoma), or severe immunological diseases (e.g., HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy).

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Daxas (roflumilast). Nycomed Inc, Princeton, NJ.